Search clinical trials for: FRα peptide plus Adjuvant (GM-CSF)

Total 120 results

Marker Therapeutics, Inc.

Terminated

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Ovarian Cancer | Platinum Sensitive Ovarian Cancer

United States
COL George Peoples, MD, FACS

Completed

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

Ovarian Cancer | Endometrial Cancer | Peritoneal Cancer | Fallopian Cancer

United States
National Cancer Institute (NCI)

Completed

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Breast Ductal Carcinoma In Situ

United States
Cancer Insight, LLC

Completed

Immunotherapy Vaccine and Herceptin in Breast Cancer

Breastcancer
Craig L Slingluff, Jr

Completed

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma (MEL37)

Melanoma

United States
San Antonio Military Medical Center
NuGenerex Immuno-Oncology; Norwell, Inc.

Completed

Vaccine Therapy in Treating Patients With Breast Cancer

Breast Cancer

United States, Germany, Greece
Bionor Immuno AS

Completed

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

HIV-1 Infection

Norway
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Chronic Myeloid Leukemia (CML)

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Rhabdomyosarcoma | Ewing's Sarcoma

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
University Children's Hospital Tuebingen
German Cancer Research Center; University Hospital Tuebingen; Universität Tübingen

Completed

Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL

Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults

Germany
Hubro Therapeutics AS
Quotient Sciences

Completed

Safety and Immune Response to FMPV-1

Colorectal Cancer

United Kingdom
University of Virginia

Completed

Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38 (MEL38)

Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Sellas Life Sciences Group
United States Department of Defense

Completed

WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

Malignant Pleural Mesothelioma

United States
Xinhua Hospital, Shanghai Jiao Tong University...

Unknown

G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor

Lymphoma | Acute Myeloid Leukemia | Neuroblastoma | Retinoblastoma | Hepatoblastoma | Acute Lymphoid Leukemia

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma

Lymphoma

United States
Jennerex Biotherapeutics
Green Cross Corporation

Completed

A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma

Neoplasms, Liver

Korea, Republic of
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

Carcinoma, Hepatocellular

United States, Korea, Republic of, Canada
Hospital Universitário Professor Edgard Santos
Oswaldo Cruz Foundation

Completed

Miltefosine and GM-CSF in Cutaneous Leishmaniasis

Cutaneous Leishmaniasis

Brazil
Second Affiliated Hospital, School of Medicine,...
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Resectable Esophageal Cancer

China
Zhejiang Provincial People's Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Resectable Pancreatic Cancer

China
George E. Peoples
Genentech, Inc.; Sellas Life Sciences Group

Completed

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Breast Cancer

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP

HIV Infections

United States
Galena Biopharma, Inc.

Completed

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)

Breast Cancer With Low to Intermediate HER2 Expression

United States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
H. Lee Moffitt Cancer Center and Research Institute
Innovive Pharmaceuticals

Completed

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

Leukemia

United States
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

Hodgkin's Disease

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

Colorectal Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia in Remission | Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Previously Treated Myelodysplastic Syndromes | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess...

United States
Ultimovacs ASA

Active, not recruiting

A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer (UV1/hTERT2012P)

Prostate Cancer

Norway
Ahmad Tarhini
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Intraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)

United States
University Hospital Tuebingen

Unknown

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides (UroRCC)

Renal Cell Cancer | Advanced Renal Cell Cancer
National Institute of Allergy and Infectious Diseases...

Completed

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

HIV Infections

United States, Thailand
Ultimovacs ASA
Oslo University Hospital

Active, not recruiting

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (UV1-hTERT2012L)

Non-small Cell Lung Cancer

Norway
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Ovarian Endometrioid Adenocarcinoma | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Recurrent Breast Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer and other conditions

United States
Sellas Life Sciences Group

Unknown

WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Multiple Myeloma | Minimal Residual Disease | High-Risk Cancer

United States
Hoag Memorial Hospital Presbyterian

Completed

Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells (DCVaccineMel)

Metastatic Melanoma

United States
University of Florida
Immunomic Therapeutics, Inc.

Terminated

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

Glioblastoma

United States
Xiangya Hospital of Central South University

Unknown

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Melanoma (Skin)

China
Genzyme, a Sanofi Company

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

Multiple Myeloma

United States, Canada, Germany
Memorial Sloan Kettering Cancer Center

Terminated

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
Immatics Biotechnologies GmbH
BioNTech SE; University Hospital Tuebingen; BCN Peptides; EU-funded GAPVAC Consortium

Completed

GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients

Glioblastoma

Spain, Switzerland, Denmark, Germany, Netherlands
National Cancer Institute (NCI)

Completed

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Mucosal Melanoma | Iris Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanoma | Recurrent... and other conditions

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

HIV Infections

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Breast Ductal Carcinoma In Situ

United States
Sir Run Run Shaw Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors

Advanced Malignant Solid Tumor

China
Dr. Nina Bhardwaj
Cancer Research Institute, New York City

Completed

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Melanoma

United States
COL George Peoples, MD, FACS
M.D. Anderson Cancer Center

Completed

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (J65)

Breast Cancer | Ovarian Cancer

United States

Search clinical trials for: FRα peptide plus Adjuvant (GM-CSF)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations